cover
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
-
Editorial Address
-
Location
Kota surabaya,
Jawa timur
INDONESIA
Indonesian Journal of Tropical and Infectious Disease
Published by Universitas Airlangga
ISSN : 20851103     EISSN : 23560991     DOI : -
Core Subject : Health, Science,
This journal is a peer-reviewed journal established to promote the recognition of emerging and reemerging diseases specifically in Indonesia, South East Asia, other tropical countries and around the world, and to improve the understanding of factors involved in disease emergence, prevention, and elimination. The journal is intended for scientists, clinicians, and professionals in infectious diseases and related sciences. We welcome contributions from infectious disease specialists in academia, industry, clinical practice, public health, and pharmacy, as well as from specialists in economics, social sciences and other disciplines.
Arjuna Subject : -
Articles 382 Documents
Resistance Pattern of Anti-TB Drugs in Drug-Resistant TB of Pulmonary Tuberculosis Patients in Dr. Soetomo Academic Hospital, Surabaya, Indonesia Marsha Maritsa, Olivia; Mertaniasih, Ni Made; Permatasari, Ariani; Kusmiati, Tutik
Indonesian Journal of Tropical and Infectious Disease Vol. 13 No. 2 (2025)
Publisher : Institute of Topical Disease Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/ijtid.v13i2.66525

Abstract

Pulmonary tuberculosis is an infectious disease that can be transmitted through the air due to infection with Mycobacterium tuberculosis bacteria. According to the WHO, TB is the second-highest cause of death in infectious diseases in the world. This study aims to determine patterns of anti-TB drug resistance in drugresistant TB patients in Dr. Soetomo Academic Hospital from January 2022 to December 2023. This was a descriptive retrospective using patient medical record data in Dr. Soetomo Academic Hospital for the period January 2022 - December 2023. This study included 261 drug resistant pulmonary TB patients, the majority of whom were new TB patients (61.3%). Anti-TB drug resistancewas most prevalent in RR-TB (43.7%), with the highest number of new cases (28.4%). Drug susceptibility test showed High-dose Isoniazid (INHHD) had a high resistance rate (56%). Isoniazid (H) had a high resistance rate (66%). Pyrazinamide (Z) showed high sensitivity (66%). Levofloxacin (Lfx) showed high sensitivity (89%). High-dose Moxifloxacin (MfxHD) high sensitivity level (94%). Moxifloxacin (Mfx) high sensitivity level (92%). Bedaquiline (Bdq) high sensitivity level (98%). Linezolid (Lzd) high sensitivity level (99%). Clofazimine (Cfz) high sensitivity level (97%). Amikacin (Amk) high sensitivity level (100%). Drug-resistant pulmonary TB patients recently show a high drug sensitivity pattern to the second-line anti-TB drugs. MTB has become resistant to Isoniazid. However, it is still sensitive to Pyrazinamide by 66% and Levofloxacin by 89%. Moxifloxacin, Bedaquilin, Linezolid, Clofazimine, and Amikacin have high sensitivity >90%.
Synthesis and Characterization of Cu(II)-EDTA Complexes: Antibacterial Studies (Escherichia coli, Staphylococcus aureus) and Inhibition of Dengue Virus Serotype 2 in Vero Cell Kinetasari, Theresia Janice; Sucipto, Teguh Hari; Nugroho, Browi; Hariyono, Hariyono; Rehman, Saifur
Indonesian Journal of Tropical and Infectious Disease Vol. 13 No. 2 (2025)
Publisher : Institute of Topical Disease Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/ijtid.v13i2.69005

Abstract

The Cu(II)-EDTA complex is known to have antibacterial and antiviral potential, but its effectiveness against pathogenic bacteria and dengue virus serotype 2 (DENV-2) still needs to be studied. This study synthesized and characterized the Cu(II)-EDTA complex of CuSO4 precursors, and then tested the antibacterial activity against Escherichia coli and Staphylococcus aureus, as well as the antiviral activity against DENV-2 in Vero cells. This study successfully synthesized and characterized the Cu(II)-EDTA complex using CuSO4 as a precursor through the solvothermal method, producing blue crystals with a Cu ratio of 1:1. DSC analysis showed thermal stability up to 250°C with an endothermal peak at 270-300°C. The particles are 6.31 nm in size with a PDI of 0.076, indicating uniform distribution with nanoparticle size (<100 nm). FTIR confirms the formation of the complex through significant shifts in the O-H and C=O bands. SEM shows a layered morphology that can affect the solubility and release of substances. UV-Vis shows maximum absorbance peaks of EDTA at 244 nm and CuSO4 at 740 nm. Antibacterial tests of Cu(II)-EDTA against E. coli and S. aureus showed that Cu(II)-EDTA had less activity than pure CuSO4. For DENV-2, CuSO4 was more effective with an EC50 value of 77.86 μg/mL, lower than Cu(II)-EDTA 356.13 μg/mL, indicating that CuSO4 was better at inhibiting viral replication.